Teijin Ltd (3401) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH33444D
- Pages: 44
- December 2018
- Total Views:1196
- Region : Asia
- GlobalData
- Equity Research Report
Details
Summary
Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.
Teijin Ltd (3401)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Licensing Agreements 18
Teijin Enters into Licensing Agreement with Merz Pharma 18
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19
Teijin Enters into Licensing Agreement with Radius Health 20
Merck Enters into Licensing Agreement with Teijin Pharma 21
Amgen Enters into Licensing Agreement with Teijin Pharma 22
Teijin Pharma Enters into Licensing Agreement with Versartis 23
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24
Debt Offering 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26
Acquisition 27
Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27
Teijin Ltd-Key Competitors 28
Teijin Ltd-Key Employees 29
Teijin Ltd-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 33
Recent Developments 34
Financial Announcements 34
May 09, 2018: Teijin: Consolidated Financial Statements Summary For the year ended March 31, 2018 34
May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37
Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
List Of Figure
List of Figures
Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Enters into Licensing Agreement with Merz Pharma 18
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19
Teijin Enters into Licensing Agreement with Radius Health 20
Merck Enters into Licensing Agreement with Teijin Pharma 21
Amgen Enters into Licensing Agreement with Teijin Pharma 22
Teijin Pharma Enters into Licensing Agreement with Versartis 23
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26
Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27
Teijin Ltd, Key Competitors 28
Teijin Ltd, Key Employees 29
Teijin Ltd, Other Locations 31
Teijin Ltd, Subsidiaries 31
Teijin Ltd, Joint Venture 33
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Teijin Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, polyester films, resin products, chemical products, IT products, pharmaceuticals, medical devices and water purification systems. The company offers pharmaceuticals for treating bone and joint diseases, respiratory diseases, cardiovascular and metabolic diseases, infectious and other diseases. Teijin operates facilities in America, Europe, Asia and Japan. The company sells its products in Asia, America, and Europe. Teijin is headquartered in Osaka, Japan.
Teijin Ltd (3401)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Teijin Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Licensing Agreements 18
Teijin Enters into Licensing Agreement with Merz Pharma 18
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19
Teijin Enters into Licensing Agreement with Radius Health 20
Merck Enters into Licensing Agreement with Teijin Pharma 21
Amgen Enters into Licensing Agreement with Teijin Pharma 22
Teijin Pharma Enters into Licensing Agreement with Versartis 23
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24
Debt Offering 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26
Acquisition 27
Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27
Teijin Ltd-Key Competitors 28
Teijin Ltd-Key Employees 29
Teijin Ltd-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Joint Venture 33
Recent Developments 34
Financial Announcements 34
May 09, 2018: Teijin: Consolidated Financial Statements Summary For the year ended March 31, 2018 34
May 09, 2017: Teijin Reports Revenue Of JPY741.3 Billion In Fiscal 2017 37
Feb 06, 2017: TEIJIN:Consolidated Financial Statements For Nine Months Ended December 31 2016 38
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
List Of Figure
List of Figures
Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Teijin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Teijin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Teijin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Teijin Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Teijin Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Teijin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Teijin Pharma Enters into Discovery Agreement with PeptiDream 12
Teijin Enters into Distribution Agreement with Taisho Pharma 13
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 14
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 15
Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 16
NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma 17
Teijin Enters into Licensing Agreement with Merz Pharma 18
Teijin Enters into Licensing Agreement with JCR Pharma for JTR-161 19
Teijin Enters into Licensing Agreement with Radius Health 20
Merck Enters into Licensing Agreement with Teijin Pharma 21
Amgen Enters into Licensing Agreement with Teijin Pharma 22
Teijin Pharma Enters into Licensing Agreement with Versartis 23
Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 24
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2021 25
Teijin Raises USD169.42 Million in Public Offering of Bonds Due 2018 26
Teijin Acquires 10% Stake In Kyorin For USD 197 Million 27
Teijin Ltd, Key Competitors 28
Teijin Ltd, Key Employees 29
Teijin Ltd, Other Locations 31
Teijin Ltd, Subsidiaries 31
Teijin Ltd, Joint Venture 33
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Teijin Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020